Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update
REDWOOD CITY, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. NASDAQ:RZLT (“Rezolute” or the “Company”), a late-stage ultra-rare rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today reported financial results and provided a bus…